Kidney Cancer Trial, Recruiting NCT06278506 Sponsor: Karolinska University Hospital Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06278506
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 99 years old
  • People whose overall health makes them a suitable candidate for both a heat/cold-based tumour destruction procedure (ablation) and surgery
  • People with a tumour that started in the kidney (not one that spread from elsewhere)
  • People whose kidney tumour measures 3 centimetres or smaller
  • People whose tumour is at an early stage, meaning it has not visibly grown into nearby blood vessels or spread outside the kidney
  • People whose tumour is located in a position that allows both ablation and surgical removal to be considered
  • People who show no signs of cancer spread (metastasis) on imaging scans
  • People who have had a biopsy confirming the tumour is cancerous
  • People whose biopsy results show a tumour grade of ISUP I, II, or III (a measure of how abnormal the cancer cells look, with lower numbers generally indicating less aggressive cells)

Who may not be able to join:

  • People who have imaging scan results showing signs that the cancer has spread to other parts of the body
  • People who have more than one kidney tumour present at the same time
  • People whose biopsy shows an ISUP grade IV tumour or a particularly aggressive type of cell growth called sarcomatoid features
  • People who have had another cancer that had spread (metastasised) within the past five years
  • People who are not able to give informed consent to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anders Kjellman, MD, PhD, Karolinska University Hospital

Phone: +46736995258

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Karolinska University Hospital
Registry
ClinicalTrials.gov
Start date
31 January 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Number of participants with surgical complications according to Clavien-Dindo grade 2-5; Radiological signs of a residual tumor at the 6-month follow-up; Number of postoperative hospitalization days (LOS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov